{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:42:19Z","timestamp":1777934539547,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T00:00:00Z","timestamp":1632441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Eribulin\u2019s clinical benefit remains unclear; so, studies analyzing its effectiveness in routine clinical practice are interesting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>This is a multicenter, retrospective study including patients with human epidermal growth factor receptor-2-negative metastatic breast cancer which assesses effectiveness and safety of eribulin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 140 women were included, with a median age of 57 years. The median overall survival and progression-free survival were 8.8 (95% confidence interval: 6.1\u201311.4) and 2.8 months (95% confidence interval: 2.5\u20133.1), respectively. For patients with hormonal receptor expression, a significantly longer progression-free survival was observed: 3.4 (95%confidence interval: 2.3\u20134.5) versus triple negative: 2.0 (95%confidence interval: 1.7\u20132.3) months, p\u2009=\u20090.003. Also, those who had received capecitabine prior to eribulin had a higher median overall survival than those who had not received it (9.5 months, 95% confidence interval: 6.6\u201312.5 vs. 4.8 months, 95% confidence interval: 3.4\u20136.2; p\u2009=\u20090.001). When only triple-negative patients were included, median overall survival was 6.5 (95% confidence interval: 0.1\u201316.2) for those who had received previous capecitabine versus 4.3 (95% confidence interval: 2.8\u20135.8) months for patients who had not received it; p\u2009=0.006. The safety profile of eribulin was adequate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Effectiveness of eribulin in a real-life human epidermal growth factor receptor-2--negative population is lower than that observed in clinical trials. Its benefit seems to be higher in patients with hormonal receptor expression and patients who had received capecitabine prior to eribulin. The safety profile of eribulin is adequate.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10781552211038241","type":"journal-article","created":{"date-parts":[[2021,9,24]],"date-time":"2021-09-24T07:30:38Z","timestamp":1632468638000},"page":"1573-1582","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and safety of eribulin for human epidermal growth factor receptor 2 negative metastatic breast cancer in a real-world population"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7186-0572","authenticated-orcid":false,"given":"Roc\u00edo","family":"D\u00edaz-Acedo","sequence":"first","affiliation":[{"name":"Pharmacy Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Artacho Criado","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Jim\u00e9nez Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital Virgen del Roc\u00edo, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Guti\u00e9rrez Pizarraya","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Galv\u00e1n Banqueri","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Rodr\u00edguez-de-la-Borbolla-Artacho","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Antonio","family":"Marcos Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital Virgen Macarena, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther","family":"M\u00e1rquez Saavedra","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Universitary Hospital of Valme, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2021,9,24]]},"reference":[{"key":"bibr1-10781552211038241","unstructured":"Breast. Globocan 2020. Available from: https:\/\/gco.iarc.fr\/today\/data\/factsheets\/cancers\/20-Breast-fact-sheet.pdf (accessed 4 January 2021)."},{"key":"bibr2-10781552211038241","first-page":"552","volume":"17","author":"Telli ML","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"bibr3-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.010"},{"key":"bibr4-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60070-6"},{"key":"bibr5-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.4892"},{"key":"bibr6-10781552211038241","unstructured":"Halaven\u00ae public assessment report. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/halaven-epar-public-assessment-report_en.pdf (accessed 4 January 2021)."},{"key":"bibr7-10781552211038241","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (AEMPS). Informe de Posicionamiento Terap\u00e9utico de eribulina (Halaven\u00ae) en el c\u00e1ncer de mama. 2015. Available from: https:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/eribulina-Halaven.pdf?x53593. (accessed 4 January 2021)."},{"key":"bibr8-10781552211038241","unstructured":"ESMO-Magnitude of clinical benefit scale (ESMO-MCBS). Available from: https:\/\/www.esmo.org\/guidelines\/esmo-mcbs?hit=ehp (accessed 4 January 2021)."},{"key":"bibr9-10781552211038241","unstructured":"European Platform of Cancer Research. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. 2017. Available from: https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_v5_Quick_Reference_5x7.pdf (accessed 4 January 2021)."},{"key":"bibr10-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-3144-y"},{"key":"bibr11-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw203"},{"key":"bibr12-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32402"},{"key":"bibr13-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-019-0367-x"},{"key":"bibr14-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1705"},{"key":"bibr15-10781552211038241","first-page":"1","volume":"9","author":"Manso L","year":"2019","journal-title":"Breast J"},{"key":"bibr16-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1159\/000489063"},{"key":"bibr17-10781552211038241","doi-asserted-by":"publisher","DOI":"10.7150\/jca.8748"},{"key":"bibr18-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2018.12.012"},{"key":"bibr19-10781552211038241","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3567-y"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038241","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552211038241","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552211038241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:25:22Z","timestamp":1777688722000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552211038241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,24]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.1177\/10781552211038241"],"URL":"https:\/\/doi.org\/10.1177\/10781552211038241","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,24]]}}}